These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11565539)

  • 21. Further evidence that activated protein C resistance affects protein C coagulant activity assays.
    Jennings I; Kitchen S; Cooper PC; Rimmer JE; Woods TA; Preston FE
    Thromb Haemost; 2000 Jan; 83(1):171-2. PubMed ID: 10669173
    [No Abstract]   [Full Text] [Related]  

  • 22. Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels?
    Lunghi B; Scanavini D; Girelli D; Legnani C; Bernardi F
    J Thromb Haemost; 2005 Feb; 3(2):415-6. PubMed ID: 15670066
    [No Abstract]   [Full Text] [Related]  

  • 23. Central retinal artery occlusion in a patient homozygous for factor V Leiden.
    Larsson J
    Am J Ophthalmol; 2000 Jun; 129(6):816-7. PubMed ID: 10927002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K; Dahlbäck B; Nicolaes GA
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor V Cambridge mutation and activated protein C resistance assays.
    Le Cam-Duchez V; Chrétien MH; Saugier-Veber P; Borg JY
    Thromb Haemost; 2006 Mar; 95(3):581-3. PubMed ID: 16525593
    [No Abstract]   [Full Text] [Related]  

  • 27. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis.
    Castaman G; Tosetto A; Ruggeri M; Rodeghiero F
    Br J Haematol; 1999 Jul; 106(1):232-6. PubMed ID: 10444192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An underestimated combination of opposites resulting in enhanced thrombotic tendency.
    Simioni P; Castoldi E; Lunghi B; Tormene D; Rosing J; Bernardi F
    Blood; 2005 Oct; 106(7):2363-5. PubMed ID: 15961511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FV and APC resistance: the plot thickens.
    Castoldi E
    Blood; 2014 Apr; 123(15):2288-9. PubMed ID: 24723678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factor V variants, activated protein C resistance and venous thromboembolism.
    Simioni P; Kalafatis M; Manfrin D; Tormene D; Girolami A
    Blood Coagul Fibrinolysis; 1998 Oct; 9(7):661-2. PubMed ID: 9863717
    [No Abstract]   [Full Text] [Related]  

  • 31. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 32. Retinal vascular occlusion and deficiencies in the protein C pathway.
    Gamel J
    Am J Ophthalmol; 2000 Jan; 129(1):112-3. PubMed ID: 10653431
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of Phenotypic Activated Protein C Resistance Testing With a Genetic Assay for Factor V Leiden.
    Murphy CH; Sabath DE
    Am J Clin Pathol; 2019 Feb; 151(3):302-305. PubMed ID: 30423028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation.
    Parker J; Pagliuca A; Kitiyakara T; Whitehead M; Heaton N; O'Grady J; Arya R
    Blood; 2001 Apr; 97(8):2525-6. PubMed ID: 11307773
    [No Abstract]   [Full Text] [Related]  

  • 35. Oral contraceptive pills and inherited thrombophilia in a young woman with deep venous thrombosis.
    Mahfouz RA; Otrock ZK; Ghasham MA; Sabbagh AS; Taher AT; Bazarbachi A
    East Mediterr Health J; 2009; 15(1):235-8. PubMed ID: 19469449
    [No Abstract]   [Full Text] [Related]  

  • 36. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
    Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
    Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of the Factor V Leiden Mutation Arg534Gln in Western Region of Saudi Arabia: Functional Alteration and Association Study With Different Populations.
    Athar M; Abduljaleel Z; Ghita IS; Albagenny AA; Halawani SH; Alkazmi MM; Elbjeirami WM; Alquthami K; Alkhuzae MM; Ragab FM; Al-Allaf FA
    Clin Appl Thromb Hemost; 2021; 27():1076029620978532. PubMed ID: 33448877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebral venous thrombosis associated to homozygous factor V Leiden mutation in a female of Syrian origin.
    Mira Y; Alfaro A; Estellés A; Vayá A; Ferrando F; Villa P
    Haematologica; 2002 Jan; 87(1):ELT02. PubMed ID: 11801486
    [No Abstract]   [Full Text] [Related]  

  • 39. High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary.
    Balogh I; Póka R; Losonczy G; Muszbek L
    Thromb Haemost; 1999 Nov; 82(5):1555-6. PubMed ID: 10595655
    [No Abstract]   [Full Text] [Related]  

  • 40. The discovery of activated protein C resistance.
    Dahlbäck B
    J Thromb Haemost; 2003 Jan; 1(1):3-9. PubMed ID: 12871530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.